Product Description for Coagulation factor VIII (F8)
Mouse anti Human Coagulation factor VIII (F8) 104.
Presentation: Ascites
Product is tested for Enzyme Immunoassay, Functional assay, Western blot / Immunoblot.
Presentation: Ascites
Product is tested for Enzyme Immunoassay, Functional assay, Western blot / Immunoblot.
Properties for Coagulation factor VIII (F8)
| Product Category | Primary Antibodies |
|---|---|
| Quantity | 1 ml |
| Synonyms | AHF, Antihemophilic factor, F8C, Procoagulant component |
| Presentation | Ascites |
| Reactivity | Hu |
| Applications | E, FN, WB |
| Clonality | Monoclonal |
| Clone | 104 |
| Host | Mouse |
| Isotype | IgG2a |
| Shipping to | Worldwide |
| PDF datasheet | View Datasheet |
| Manufacturer | OriGene Technologies GmbH |
| Material safety datasheet | MSDS for Monoclonal Antibodies (de) |
Datasheet Extract
| Immunogen |
|
|---|---|
| Add. information | This antibody can inhibit Factor VIII activity in coagulation assays. |
| Application | Suitable for use in ELISA and Western blot to detect and quantitate human Factor VIII. Functional assays. |
| Background | Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein. |
| Storage | Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20 °C to - 70 °C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch. |
| Format |
|
| Specificity |
|
| Gene ID | 2157 |
Accessory Products
Proteins and/or Positive Controls
Proteins for Coagulation factor VIII (F8) (17 products)
| Catalog No. | Species | Pres. | Purity | Source | |||
|---|---|---|---|---|---|---|---|
| AR10286PU-L |
Coagulation factor VIII (F8) |
||||||
|
Human | Purified | |||||
| OriGene Technologies GmbH | |||||||
| AR10286PU-N |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | |||||
| OriGene Technologies GmbH | |||||||
| AR10286PU-S |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | |||||
| OriGene Technologies GmbH | |||||||
| AR10287PU-L |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | > 97.0% as determined by SDS-PAGE. | CHO cells | |||
| OriGene Technologies GmbH | |||||||
| AR10287PU-N |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | > 97.0% as determined by SDS-PAGE. | CHO cells | |||
| OriGene Technologies GmbH | |||||||
| AR10287PU-S |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | > 97.0% as determined by SDS-PAGE. | CHO cells | |||
| OriGene Technologies GmbH | |||||||
| PA1292 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified |
> 98 % purified by proprietary chromatographic techniques, purity is greater than 98.0 % as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. |
Plasma | |||
| OriGene Technologies GmbH | |||||||
| PA1292X |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified |
> 98 % purified by proprietary chromatographic techniques, purity is greater than 98.0 % as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. |
Plasma | |||
| OriGene Technologies GmbH | |||||||
| PA1292XC |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified |
> 98 % purified by proprietary chromatographic techniques, purity is greater than 98.0 % as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. |
Plasma | |||
| OriGene Technologies GmbH | |||||||
| PA1293 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified |
> 98 % Purified by proprietary chromatographic techniques, purity is reater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. |
CHO cells | |||
| OriGene Technologies GmbH | |||||||
| PA1293X |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified |
> 98 % Purified by proprietary chromatographic techniques, purity is reater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. |
CHO cells | |||
| OriGene Technologies GmbH | |||||||
| PA1293XC |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified |
> 98 % Purified by proprietary chromatographic techniques, purity is reater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained. |
CHO cells | |||
| OriGene Technologies GmbH | |||||||
| H00002157-P01 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | ||||||
| Abnova Taiwan Corp. | |||||||
| H00002157-P01-10 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | |||||
| Abnova Taiwan Corp. | |||||||
| H00002157-P01-25 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | Purified | |||||
| Abnova Taiwan Corp. | |||||||
| H00002157-Q01-10 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | 12.5% SDS-PAGE Stained with Coomassie Blue. | in vitro transl. | ||||
| Abnova Taiwan Corp. | |||||||
| H00002157-Q01-25 |
Coagulation factor VIII (F8) |
||||||
|
|
Human | 12.5% SDS-PAGE Stained with Coomassie Blue. | in vitro transl. | ||||
| Abnova Taiwan Corp. | |||||||
Positive controls for Coagulation factor VIII (F8) (3 products)
| Catalog No. | Species | Pres. | Purity | Source | |||
|---|---|---|---|---|---|---|---|
| H00002157-T01 |
F8 293T Cell Transient Overexpression Lysate(Denatured) |
||||||
|
|||||||
| Abnova Taiwan Corp. | |||||||
| LY402745 |
F8 overexpression lysate |
||||||
|
|||||||
| OriGene Technologies, Inc. | |||||||
| NBL1-10413 |
Factor VIII Lysate |
||||||
![Western Blot: Factor VIII Lysate [NBL1-10413] - Western Blot experiments.
Left-Control; Right -Over-expression Lysate for F8](https://m1.acris-antibodies.com/catalog/product/cache/1/small_image/50x50/9df78eab33525d08d6e5fb8d27136e95/Novus/Factor%20VIII%20Lysate-Western%20Blot-NBL1-10413-img0001.jpg) |
|||||||
| Novus Biologicals Inc. | |||||||
Recommended Secondary Antibodies for Coagulation factor VIII (F8) (11 products)
| Catalog No. | Host | Clone/Iso. | Pres. | React. | Applications | ||
|---|---|---|---|---|---|---|---|
| R1253AP |
Mouse IgG (H+L chain) antibody |
||||||
|
|
Rabbit | AP | C, E, WB | ||||
| OriGene Technologies GmbH | |||||||
| R1253B |
Mouse IgG (H+L chain) antibody |
||||||
|
|
Rabbit | Biotin | C, E, WB | ||||
| OriGene Technologies GmbH | |||||||
| R1253F |
Mouse IgG (H+L chain) antibody |
||||||
|
|
Rabbit | FITC | E, ICC/IF | ||||
| OriGene Technologies GmbH | |||||||
| R1253HRP |
Mouse IgG (H+L chain) antibody |
||||||
|
Rabbit | HRP | C, E, WB | ||||
| OriGene Technologies GmbH | |||||||
| R1253TR |
Mouse IgG (H+L chain) antibody |
||||||
|
|
Rabbit | Texas Red | ICC/IF | ||||
| OriGene Technologies GmbH | |||||||
| R1403R |
Mouse IgG (H+L chain), F(ab)2 Fragment, adsorbed antibody |
||||||
|
|
Rabbit | PE | F | ||||
| OriGene Technologies GmbH | |||||||
| R1405R |
Mouse IgG (H+L chain), F(ab)2 Fragment, adsorbed antibody |
||||||
|
|
Goat | PE | |||||
| OriGene Technologies GmbH | |||||||
| R1455R |
Mouse IgG (H+L chain), F(ab)2 Fragment, adsorbed antibody |
||||||
|
|
Donkey | PE | |||||
| OriGene Technologies GmbH | |||||||
| R1457C2 |
Mouse IgG (H+L chain), adsorbed antibody |
||||||
|
|
Goat | Cy2 | |||||
| OriGene Technologies GmbH | |||||||
| R1457C3 |
Mouse IgG (H+L chain), adsorbed antibody |
||||||
|
|
Goat | Cy3 | |||||
| OriGene Technologies GmbH | |||||||
| R1457C5 |
Mouse IgG (H+L chain), adsorbed antibody |
||||||
|
|
Goat | Cy5 | |||||
| OriGene Technologies GmbH | |||||||
Compare Products
You have no items to compare.
My Cart
You have no items in your shopping cart.
